ABSTRACT
Seed treatment is important for protecting seed and seedling from pests and/ or pathogens. Seed treatment can be performed generally in two ways: industrial seed treatment (IST), performed by seed companies, or on-farm treatment (OFT). These treatment technologies will affect the final quality of the process. Therefore, the objective of this study was to characterize the seed quality profile of ISTs and OFTs in Brazilian agribusiness in terms of functional quality and dose application effectiveness (DAE). Seed samples treated by both processes were collected in 6 producing states of Brazil, Mato Grosso, Goias, Parana, Minas Gerais, Sao Paulo, and Santa Catarina. To evaluate the functional quality of the treatments, the coating percentage was determined by high-resolution image analysis with GroundEye (R) equipment, and the insecticide active ingredient DAE amount was determined with high-performance liquid chromatography (HPLC). Image analysis proved to be a promising technique to evaluate seed coating, in addition, samples treated with "on farm" technology had greater variation and heterogeneity in coating and active ingredient dose, while samples treated industrially showed greater homogeneity, uniformity, effectiveness of applied products. There was a strong positive correlation between coating with phytosanitary products and DAE in treated corn seeds, important parameters in the evaluation of the quality of the treatment.
ABSTRACT
Background: As a reaction to the COVID-19 pandemic, a nation-wide lockdown was enforced in Brazil in March 2020, cancer care was impacted, and cancer screening reduced. Therefore, an increase in cancer diagnoses at more advanced stages was expected. In this study, we extracted data from our nationwide real-world database to evaluate the impact of the COVID-19 pandemic on the stage at diagnosis of breast cancer (BC) cases. Methods: We explored curated electronic medical record data of female patients, over 18 years of age, diagnosed with BC and with established disease stage based on the AJCC 8th edition, who started treatment or follow-up in the Oncoclínicas (OC) between Jan 1, 2018, and Dec 31, 2021. The primary objective was to compare stage distribution at first visit during COVID- 19 pandemic (2020-2021) with a historical control cohort from a period prior to the pandemic (2018- 2019). We investigated stage distribution according to age at diagnosis and tumor ER/HER2 subtype in univariate models. Associations were considered significant if they had a minimum significance (P < 0.1 in Chi-square test). The historical numbers of patients with BC at OC make it possible to identify differences in the prevalence of stages in the order of 5% comparing pre and post pandemic periods with a statistical power greater than 80%. Results: We collected data for 11,752 patients with initial diagnosis of BC, with 6,492 patients belonging to the pandemic (2020-2021) and 5,260 patients to the pre-pandemic period (2018-2019). For both ER+/ HER2- and HER2+ tumors, there was a lower percentage of patients with early-stage (defined as stage I-II) in the years 2020-2021 vs 2018-2019 and a considerable increase in advanced-stage disease (defined as stage IV). For triple negative BC (TNBC), there was a significant higher percentage of patients with advanced-stage disease in the pandemic vs pre-pandemic period (table 1). Age over 50 years was associated with a greater risk of advanced stage at diagnosis after the onset of the pandemic, with an absolute increase of 7% (P twosided <0.01). Conclusions: We observed a substantial increase in cases of advanced-stage BC in OC institutions as a result of delays in BC diagnoses due to the COVID-19 pandemic. The impact appeared greater in older adults, potentially because of stricter confinement in this group.